避孕暴露与育龄妇女尿路感染风险相关:一项病例对照研究。

IF 1.9 4区 医学 Q3 OBSTETRICS & GYNECOLOGY European Journal of Contraception and Reproductive Health Care Pub Date : 2023-02-01 DOI:10.1080/13625187.2022.2156278
Claire Lo, Abin Abraham, Cosmin A Bejan, Seth A Reasoner, Mario Davidson, Loren Lipworth, David M Aronoff
{"title":"避孕暴露与育龄妇女尿路感染风险相关:一项病例对照研究。","authors":"Claire Lo,&nbsp;Abin Abraham,&nbsp;Cosmin A Bejan,&nbsp;Seth A Reasoner,&nbsp;Mario Davidson,&nbsp;Loren Lipworth,&nbsp;David M Aronoff","doi":"10.1080/13625187.2022.2156278","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Although non-barrier contraception is commonly prescribed, the risk of urinary tract infections (UTI) with contraceptive exposure is unclear.</p><p><strong>Materials and methods: </strong>Using data from Vanderbilt University Medical Centre's deidentified electronic health record (EHR), women ages 18-52 were randomly sampled and matched based on age and length of EHR. This case-control analysis tested for association between contraception exposure and outcome using UTI-positive (UTI+) as cases and upper respiratory infection+ (URI+) as controls.</p><p><strong>Results: </strong>24,563 UTI + cases (mean EHR: 64.2 months; mean age: 31.2 years) and 48,649 UTI-/URI + controls (mean EHR: 63.2 months; mean age: 31.9 years) were analysed. In the primary analysis, UTI risk was statistically significantly increased for the oral contraceptive pill (OCP; OR = 1.10 [95%CI = 1.02-1.11], <i>p</i> ≤ 0.05), intrauterine device (IUD; OR = 1.13 [95%CI = 1.04-1.23], <i>p</i> ≤ 0.05), etonogestrel implant (Nexplanon<sup>®</sup>; OR = 1.56 [95% CI = 1.24-1.96], <i>p</i> ≤ 0.05), and medroxyprogesterone acetate injectable (Depo-Provera<sup>®</sup>; OR = 2.16 [95%CI = 1.99-2.33], <i>p</i> ≤ 0.05) use compared to women not prescribed contraception. A secondary analysis that included <i>any</i> non-IUD contraception, which could serve as a proxy for sexual activity, demonstrated a small attenuation for the association between UTI and IUD (OR = 1.09 [95%CI = 0.98-1.21], <i>p</i> = 0.13).</p><p><strong>Conclusion: </strong>This study notes potential for a small increase in UTIs with contraceptive use. Prospective studies are required before this information is applied in clinical settings.</p><p><strong>Condensation: </strong>Although non-barrier contraception is commonly prescribed, the risk of urinary tract infections (UTI) with contraceptive exposure is poorly understood. This large-cohort, case-control study notes potential for a small increase in UTIs with contraceptive use.</p>","PeriodicalId":50491,"journal":{"name":"European Journal of Contraception and Reproductive Health Care","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Contraceptive exposure associates with urinary tract infection risk in a cohort of reproductive-age women: a case control study.\",\"authors\":\"Claire Lo,&nbsp;Abin Abraham,&nbsp;Cosmin A Bejan,&nbsp;Seth A Reasoner,&nbsp;Mario Davidson,&nbsp;Loren Lipworth,&nbsp;David M Aronoff\",\"doi\":\"10.1080/13625187.2022.2156278\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Although non-barrier contraception is commonly prescribed, the risk of urinary tract infections (UTI) with contraceptive exposure is unclear.</p><p><strong>Materials and methods: </strong>Using data from Vanderbilt University Medical Centre's deidentified electronic health record (EHR), women ages 18-52 were randomly sampled and matched based on age and length of EHR. This case-control analysis tested for association between contraception exposure and outcome using UTI-positive (UTI+) as cases and upper respiratory infection+ (URI+) as controls.</p><p><strong>Results: </strong>24,563 UTI + cases (mean EHR: 64.2 months; mean age: 31.2 years) and 48,649 UTI-/URI + controls (mean EHR: 63.2 months; mean age: 31.9 years) were analysed. In the primary analysis, UTI risk was statistically significantly increased for the oral contraceptive pill (OCP; OR = 1.10 [95%CI = 1.02-1.11], <i>p</i> ≤ 0.05), intrauterine device (IUD; OR = 1.13 [95%CI = 1.04-1.23], <i>p</i> ≤ 0.05), etonogestrel implant (Nexplanon<sup>®</sup>; OR = 1.56 [95% CI = 1.24-1.96], <i>p</i> ≤ 0.05), and medroxyprogesterone acetate injectable (Depo-Provera<sup>®</sup>; OR = 2.16 [95%CI = 1.99-2.33], <i>p</i> ≤ 0.05) use compared to women not prescribed contraception. A secondary analysis that included <i>any</i> non-IUD contraception, which could serve as a proxy for sexual activity, demonstrated a small attenuation for the association between UTI and IUD (OR = 1.09 [95%CI = 0.98-1.21], <i>p</i> = 0.13).</p><p><strong>Conclusion: </strong>This study notes potential for a small increase in UTIs with contraceptive use. Prospective studies are required before this information is applied in clinical settings.</p><p><strong>Condensation: </strong>Although non-barrier contraception is commonly prescribed, the risk of urinary tract infections (UTI) with contraceptive exposure is poorly understood. This large-cohort, case-control study notes potential for a small increase in UTIs with contraceptive use.</p>\",\"PeriodicalId\":50491,\"journal\":{\"name\":\"European Journal of Contraception and Reproductive Health Care\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Contraception and Reproductive Health Care\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13625187.2022.2156278\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Contraception and Reproductive Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13625187.2022.2156278","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

目的:虽然非屏障避孕是常用的处方,但与避孕暴露尿路感染(UTI)的风险尚不清楚。材料和方法:使用范德比尔特大学医学中心的电子健康记录(EHR)的数据,随机抽取18-52岁的女性,并根据年龄和EHR的长度进行匹配。本病例-对照分析以尿路感染阳性(UTI+)病例和上呼吸道感染+ (URI+)病例为对照,检验避孕暴露与结局之间的关系。结果:尿路感染+病例24,563例(平均EHR: 64.2个月;平均年龄:31.2岁)和48,649例UTI-/URI +对照(平均EHR: 63.2个月;平均年龄:31.9岁)。在初步分析中,口服避孕药(OCP;OR = 1.10 [95%CI = 1.02-1.11], p≤0.05),宫内节育器(IUD;OR = 1.13 [95%CI = 1.04-1.23], p≤0.05),依替诺孕酮种植体(Nexplanon®;OR = 1.56 [95% CI = 1.24-1.96], p≤0.05),可注射醋酸甲孕酮(Depo-Provera®;OR = 2.16 [95%CI = 1.99-2.33], p≤0.05)。另一项纳入非宫内节育器避孕的二次分析显示,UTI和宫内节育器之间的相关性略有减弱(OR = 1.09 [95%CI = 0.98-1.21], p = 0.13)。结论:本研究注意到使用避孕药可能会导致尿路感染的小幅增加。在将这些信息应用于临床之前,需要进行前瞻性研究。冷凝:虽然非屏障避孕是常用的处方,但暴露于避孕药具的尿路感染(UTI)的风险知之甚少。这项大型队列、病例对照研究指出,使用避孕药可能会导致尿路感染的小幅增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Contraceptive exposure associates with urinary tract infection risk in a cohort of reproductive-age women: a case control study.

Purpose: Although non-barrier contraception is commonly prescribed, the risk of urinary tract infections (UTI) with contraceptive exposure is unclear.

Materials and methods: Using data from Vanderbilt University Medical Centre's deidentified electronic health record (EHR), women ages 18-52 were randomly sampled and matched based on age and length of EHR. This case-control analysis tested for association between contraception exposure and outcome using UTI-positive (UTI+) as cases and upper respiratory infection+ (URI+) as controls.

Results: 24,563 UTI + cases (mean EHR: 64.2 months; mean age: 31.2 years) and 48,649 UTI-/URI + controls (mean EHR: 63.2 months; mean age: 31.9 years) were analysed. In the primary analysis, UTI risk was statistically significantly increased for the oral contraceptive pill (OCP; OR = 1.10 [95%CI = 1.02-1.11], p ≤ 0.05), intrauterine device (IUD; OR = 1.13 [95%CI = 1.04-1.23], p ≤ 0.05), etonogestrel implant (Nexplanon®; OR = 1.56 [95% CI = 1.24-1.96], p ≤ 0.05), and medroxyprogesterone acetate injectable (Depo-Provera®; OR = 2.16 [95%CI = 1.99-2.33], p ≤ 0.05) use compared to women not prescribed contraception. A secondary analysis that included any non-IUD contraception, which could serve as a proxy for sexual activity, demonstrated a small attenuation for the association between UTI and IUD (OR = 1.09 [95%CI = 0.98-1.21], p = 0.13).

Conclusion: This study notes potential for a small increase in UTIs with contraceptive use. Prospective studies are required before this information is applied in clinical settings.

Condensation: Although non-barrier contraception is commonly prescribed, the risk of urinary tract infections (UTI) with contraceptive exposure is poorly understood. This large-cohort, case-control study notes potential for a small increase in UTIs with contraceptive use.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
11.80%
发文量
63
审稿时长
>12 weeks
期刊介绍: The Official Journal of the European Society of Contraception and Reproductive Health, The European Journal of Contraception and Reproductive Health Care publishes original peer-reviewed research papers as well as review papers and other appropriate educational material.
期刊最新文献
A randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg. Medical termination of pregnancy: people's expectations and experiences in the Netherlands. Neighbourhood environment and early menarche among adolescent girls of five countries. Postpartum contraception provision across Europe: preliminary findings from a multi country survey. Response to Daungsupawong and Wiwanitkit's Letter to the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1